In Vivo Gene Editing Therapies Offer Root-Cause Treatment for Genetic Diseases, but Efficient and Precise Liver-Targeted Delivery Remains a Critical Hurdle for Clinical Translation. Lipid Nanoparticles (LNPs), as the Mainstream Non-Viral Vector, Have Made Functionalization a Core Strategy for Enhancing Targeting Efficiency.

Xiamen Sinopeg Biotech Co., Ltd. (Sinopeg) is proud to introduce its independently innovated structure,GalNAc-PEG-DTA-5-2K. This liver-targeting functional PEG lipid, specifically designed for LNP systems, aims to provide gene editing and siRNA drug developers with a high-performance excipient option featuring a clear IP profile. It is set to empower the advancement of liver-targeted therapeutic pipelines.

I. Delivery Challenges for Liver-Targeted Gene Editing

The in vivo application of gene editing therapies hinges on the safe and precise delivery of the CRISPR system (editor mRNA and guide RNA) to target cells. LNPs have become a recognized in vivo delivery platform, owing to their excellent encapsulation and protection capabilities, low immunogenicity, and scalability for manufacturing. However, after intravenous administration, conventional LNPs are largely cleared by liver immune cells or degraded in circulation, with a limited fraction reaching hepatocytes. This restricts therapeutic efficacy and may increase off-target risks. Thus, endowing LNPs with active liver-targeting capabilities is an inevitable direction for technological advancement.

Among targeting strategies, the N-acetylgalactosamine (GalNAc) ligand stands out as a well-established and extensively validated liver-targeting approach. Its receptor, the asialoglycoprotein receptor (ASGPR), is highly expressed on the surface of hepatocytes and is not found at significant levels in other tissues. This makes the GalNAc-ASGPR pathway a highly efficient and specific natural targeting mechanism. GalNAc ligands can specifically bind to ASGPR, facilitating efficient cellular uptake via receptor-mediated endocytosis. Integrating this strategy into LNP systems offers a new design dimension for the hepatic delivery of gene editing drugs.

II. Industry Trend: GalNAc-PEG Lipids Emerge as a Consensus Direction for Liver-Targeted LNPs

In the field ofin vivogene editing, cutting-edge research from both international and domestic fronts is converging on the GalNAc-PEG lipid technology pathway.

U.S.-based Verve Therapeutics, in its second-generationin vivobase editing therapy, has incorporated GalNAc targeting ligands into its LNP delivery system, modifying the LNP surface with GalNAc-containing PEG lipids. This upgrade aims to enhance liver targeting, increase drug concentration within hepatocytes, thereby achieving effective editing at lower doses and improving drug tolerability and safety. Drawing on clinical experience from its first-generation product, Verve has made a clear targeted enhancement to its delivery vehicle, reflecting that GalNAc-LNPs have become a technological pinnacle and key development direction in this field.

Notably, several pioneering Chinese biotech companies at the forefront of gene editing have similarly identified the bottlenecks and opportunities in liver-targeted delivery, setting their sights on next-generation GalNAc-PEG liver-targeting technologies. Some of these leading domestic gene editing firms have already adopted GalNAc-PEG lipid-based LNP delivery strategies, similar to Verve-102, in their highly confidential pipelines that represent their future core competitiveness. This consensus on the technology path among leading players globally indicates that GalNAc-PEG lipids are becoming a preferred choice for liver-targeted LNP delivery and are a critical excipient supporting the development of next-generation gene editing therapies.

III. Product Analysis: The Innovative Design of GalNAc-PEG-DTA-5-2K

To address the urgent industry need for efficient, safe, and IP-clear LNP excipients for liver targeting, Xiamen Sinopeg, leveraging its robust R&D capabilities and forward-looking strategic planning, has developed our solution –GalNAc-PEG-DTA-5-2K– after years of dedicated research and rigorous validation.

GalNAc-PEG-DTA-5-2K is a liver-targeting functional PEG lipid specifically engineered for LNP systems, synergistically composed of three key moieties:

• GalNAc Targeting Head:Utilizes a GalNAc targeting group designed to bind with high affinity to the abundantly expressed asialoglycoprotein receptor (ASGPR) on hepatocyte surfaces, enabling active liver cell targeting. This design is one of the most mature liver-targeting strategies currently adopted in the industry and has been extensively validated in numerous published studies and clinical pipelines.

• PEG Spacer Arm:Provides an approximately 2 kDa long-chain PEG hydrophilic shielding layer. It fully exposes the targeting head from the LNP surface, allowing for optimal conformational freedom for efficient receptor binding, while simultaneously prolonging the circulation time of LNPsin vivoand reducing non-specific protein adsorption.

• DTA-5 Hydrophobic Anchor:A lipophilic anchoring structure specifically designed by Sinopeg for the LNP bilayer environment. Its purpose is to optimize the anchoring stability of the PEG lipid on the particle surface, thereby supporting the structural integrity of the lipid nanoparticles during circulation.

IV. Choose Sinopeg for Success and Future Security

Bringing an innovative excipient to market requires a robust industrialization platform. Choosing GalNAc-PEG-DTA-5-2K also means choosing Sinopeg's ongoing commitment to quality systems, supply chain security, and technical services.

Since its inception, Sinopeg has been dedicated to the R&D, production, and sales of polyethylene glycol (PEG) derivatives and drug delivery system excipients. The company is a nationally recognized high-tech enterprise, holding multiple granted invention patents and pending patent applications covering core product categories, establishing a systematic intellectual property layout in the key LNP excipient field. Our production facilities operate strictly in accordance with cGMP standards and hold ISO 13485 quality management system certification. Several products have US FDA Drug Master File (DMF) filings and CDE pharmaceutical excipient registrations, supporting clients' simultaneous domestic and international regulatory submissions.

The stability of core excipient supply directly impacts the R&D progress of innovative drug pipelines. Sinopeg has established a comprehensive quality control system, from raw material sourcing and synthesis processes to purification controls. Our local presence ensures a stable supply, shorter response times, and more direct technical communication, assisting clients in managing uncertainties during R&D and production.

Beyond GalNAc-PEG-DTA-5-2K, Sinopeg offers a complete portfolio of LNP excipients, including various independently patented ionizable lipids (including a series of cationic lipids with granted Chinese invention patents), high-purity helper lipids (DSPC, DOPE, etc.), cholesterol, and a variety of functional PEG lipids with different molecular weights and functional groups.

References:

1. Verve Therapeutics, Inc. Official Website and Public Pipeline Information, VERVE-102 related details;Nature Medicine(2024), VERVE-102 related research articles.

2. Verve Therapeutics, Inc. Corporate Announcements and Scientific Conference Presentations (e.g., AHA 2023/2024, etc.), comparative information on the delivery strategies of VERVE-101 and VERVE-102.

3. ASGPR-GalNAc binding mechanism reference: Spieß, M. (1990).Biochemistry, 29(43), 10009-10018. Foundational research on ASGPR expression in hepatocytes and GalNAc recognition mechanisms.